On January 27^th 2021, Shanghai Huaota Biopharmaceutical Co., Ltd. joins the BIO100+ enterprise service platform under Enmorehealthcare. Enmorehealthcare will provide Huaota with a full range of services such as brand display, online promotion, and offline communication during 2021. Huaota will also conduct a project roadshow at the 6th E-Trade Biological Industry Conference (EBC) ‘Investment Forum’ on March 13, so stay tuned!

BIO100+ aims to bring together 100+ leading innovative technology companies in China's biological industry to jointly build a platform for exchanges and cooperation across the industry chain. Looking forward to more partners joining!

About Huaota

Shanghai Huaota Biopharmaceutical Co., Ltd. (aka ‘Huaota’) was established in September 2013, and is a subsidiary of Zhejiang Huahai Pharmaceutical Co., Ltd(stock code: 600521). Huaota focuses on research and development of bio-innovative drugs within the fields of tumors, autoimmune diseases, fundus lesions, etc. Huaota has established a platform for drug development and pilot scale testing of single agent antibodies, bispecific antibodies, fusion proteins, and ADC drugs. The original solution and preparation production workshops comply with the GMP standards of China, the United States and Europe Uion, and support the production of pre-clinical and clinical phase I-II samples。

As an innovative company focusing on independent research and development, Huaota has applied for more than 20 domestic and foreign invention patents, and has nearly 30 ongoing research projects, of which 7 projects have entered key clinical trials. Including the world’s first PD-L1/VEGF bispecific fusion protein, its Phase I trial is being carried out simultaneously in China and the United States; the monoclonal antibody targeting IL-17A is about to end phase I clinical trials in New Zealand; the monoclonal antibody targeting CD137 has been approved by NMPA to enter phase I clinical trials; VEGF-Fc fusion proteins (including fundus lesions and advanced solid tumors) have all entered Phase II clinical. Meanwhile, there are more innovative cutting-edge layouts in the Huaota’s product pipeline, which will be made public in the future.

In today’s vigorous development of biopharmaceuticals, in order to achieve the company’s next stage development, Huaota adheres to the cooperation concept of independent research and development, global development, flexible and open mind. Huaota looks forward to working with industry leaders to provide high-quality, high-level new biological drugs for the global market and realize the vision of innovation change the world.

About BIO100+

BIO100+ is a brand of Enmorehealthcare, which aims to build an enterprise service platform in China's BIO field and provide enterprises with an online + offline overall solution. The platform brings together 100+ leading innovative technology companies in China's biological industry to jointly build a platform for exchanges and cooperation across the industry chain.

About Enmorehealthcare

Enmorehealthcare is committed to building a service platform in the fields of biotechnology and medical and health. We provide diversified services to enterprises through the online + offline model, promote cooperation between enterprises, capital and medical institutions, and enhance the government, associations and Corporate communication.

Offline services: Form a three-dimensional integrated service model of conference forums, high-end headhunters, and think tank experts. The conference sponsored by Enmorehealthcare began in 2009. After more than ten years, it has become the leading conference organizer in the domestic biotechnology field, and its EBC has become the most influential bio-industry conference + exhibition in China.

Online services: E-Trade Expert Activities, an online communication and learning platform created by E-Trade, has launched more than 100 online activities, covering topics such as R&D, clinical, production, entrepreneurship, investment and financing, etc. At the same time, Enmorehealthcare said, a cutting-edge media under Enmorehealthcare, provides an online communication platform for entrepreneurs and investors.